| Market Cap | 1.25B | P/E | - | EPS this Y | -466.70% | Ern Qtrly Grth | - |
| Income | -16.21M | Forward P/E | -39.00 | EPS next Y | -27.30% | 50D Avg Chg | 92.00% |
| Sales | 60.78M | PEG | -0.29 | EPS past 5Y | -61.15% | 200D Avg Chg | 109.00% |
| Dividend | N/A | Price/Book | 8.44 | EPS next 5Y | 127.60% | 52W High Chg | -11.00% |
| Recommedations | 1.60 | Quick Ratio | 8.91 | Shares Outstanding | 80.05M | 52W Low Chg | 259.00% |
| Insider Own | 19.49% | ROA | -5.70% | Shares Float | 52.10M | Beta | 0.47 |
| Inst Own | 39.24% | ROE | -16.48% | Shares Shorted/Prior | 10.94M/3.25M | Price | 15.60 |
| Gross Margin | 80.51% | Profit Margin | -26.68% | Avg. Volume | 22,091,436 | Target Price | 29.20 |
| Oper. Margin | -18.39% | Earnings Date | May 12 | Volume | 47,512,508 | Change | 15.56% |
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
| Oppenheimer | Outperform | Apr 12, 22 |
| HC Wainwright & Co. | Buy | Apr 12, 22 |
| Jefferies | Buy | Apr 13, 21 |
| HC Wainwright & Co. | Buy | Feb 24, 21 |
| HC Wainwright & Co. | Buy | Feb 11, 21 |
| HC Wainwright & Co. | Buy | Feb 9, 21 |
| Oppenheimer | Outperform | Dec 16, 20 |
| HC Wainwright & Co. | Buy | Dec 15, 20 |
| Cantor Fitzgerald | Overweight | Dec 14, 20 |